--- title: "Adaptive Biotechnologies (ADPT) news: offering" url: "https://aibio.space/companies/adaptive-biotechnologies/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ADPT offering, convertible notes and buyback news: Adaptive Biotechnologies prices upsized $300 million convertible notes." --- ADPT Adaptive Biotechnologies Corporation NASDAQ · United States # Adaptive Biotechnologies (ADPT) news ADPT offering, convertible notes and buyback news Debt Financing · 2026-06-17 ## [Adaptive Biotechnologies prices upsized $300 million convertible notes](https://aibio.space/news/adaptive-biotechnologies-prices-upsized-300-million-convertible-notes/) Adaptive Biotechnologies priced $300 million of 0% convertible senior notes due 2031, upsized from $250 million. J. Wood Capital Advisors LLC, its financial advisor on the offering, agreed to purchase about $10 million of shares. ## Latest Adaptive Biotechnologies news 1. 2026-06-15 Debt Financing [Adaptive Biotechnologies plans $250 million of convertible notes](https://aibio.space/news/adaptive-biotechnologies-plans-250-million-convertible-notes/) Adaptive Biotechnologies plans a $250 million offering of convertible senior notes due 2031 and expects to use up to $25 million of the proceeds to repurchase common stock. The interest rate and conversion terms will be set only at pricing. ## Adaptive Biotechnologies at a glance - **Ticker**: ADPT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $344.3 million ### Related companies - [CNBX Pharmaceuticals](https://aibio.space/companies/cnbx-pharmaceuticals/) OTC: CNBX - [Denali Therapeutics](https://aibio.space/companies/denali-therapeutics/) NASDAQ: DNLI - [AVVAA World Health Care Products](https://aibio.space/companies/avvaa-world-health-care-products/) OTC: AVVH - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) NASDAQ: ELVN - [Immunovant](https://aibio.space/companies/immunovant/) NASDAQ: IMVT - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) NASDAQ: SABS - [MeiraGTx Holdings](https://aibio.space/companies/meiragtx/) NASDAQ: MGTX - [CalciMedica](https://aibio.space/companies/calcimedica/) NASDAQ: CALC ### Also on NASDAQ - [CytomX Therapeutics](https://aibio.space/companies/cytomx-therapeutics/) CTMX - [Rein Therapeutics](https://aibio.space/companies/rein-therapeutics/) RNTX - [CareDx](https://aibio.space/companies/caredx/) CDNA - [MARAVAI LIFESCIENCES HOLDINGS, INC.](https://aibio.space/companies/maravai-lifesciences/) MRVI - [Sight Sciences](https://aibio.space/companies/sight-sciences/) SGHT - [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) VYGR ## What Adaptive Biotechnologies does Adaptive Biotechnologies Corporation uses sequencing and computational biology to read the adaptive immune system and develop clinical products. Its MRD business uses a highly sensitive next-generation sequencing assay to measure minimal residual disease in hematologic malignancies. The clonoSEQ clinical diagnostic test is offered to clinicians, and the clonoSEQ assay is offered to biopharmaceutical partners for drug development. clonoSEQ is the first test authorized by the FDA for detection and monitoring of MRD in multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Its Immune Medicine business offers immune receptor sequencing, licensing of its proprietary data, TCR-antigen prediction models and target discovery, with work in autoimmunity including multiple sclerosis and type 1 diabetes. In December 2025 the company entered into two non-exclusive agreements with Pfizer Inc. to leverage its TCR discovery platform in rheumatoid arthritis and broader immunology. In 2025 revenue was $277.0 million, compared with $179.0 million in 2024, and total MRD revenue was $212.3 million. | Product or program | What it is | Stage | |---|---|---| | clonoSEQ clinical test | NGS assay measuring MRD in lymphoid cancers | FDA authorized for MM, B-ALL and CLL | | clonoSEQ assay (MRD Pharma) | MRD assay offered to biopharmaceutical partners for drug development | | | Immune Medicine platform | TCR and BCR sequencing, TCR-antigen prediction and target discovery | | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm). ## Adaptive Biotechnologies annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$277.0 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | [$179.0 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | | Research and development | [$93.8 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | [$103.0 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | | Net income (loss) | [-$59.5 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | [-$159.5 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | | Cash from operations | [-$46.0 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | [-$95.2 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | | Cash and equivalents | [$70.5 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526332940/) | [$47.9 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | | Short-term investments | [$156.5 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526332940/) | [$174.4 million](https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $169.9 million, plus short-term investments of $174.4 million, $344.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Adaptive Biotechnologies Has Adaptive Biotechnologies raised money recently? Our latest story on this, dated Jun 17, 2026: "Adaptive Biotechnologies prices upsized $300 million convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/adaptive-biotechnologies-prices-upsized-300-million-convertible-notes/). Has Adaptive Biotechnologies sold convertible notes? Our latest story on this, dated Jun 17, 2026: "Adaptive Biotechnologies prices upsized $300 million convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/adaptive-biotechnologies-prices-upsized-300-million-convertible-notes/). Does Adaptive Biotechnologies have a share buyback? Our latest story on this, dated Jun 15, 2026: "Adaptive Biotechnologies plans $250 million of convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/adaptive-biotechnologies-plans-250-million-convertible-notes/). What is the ticker symbol of Adaptive Biotechnologies? Adaptive Biotechnologies Corporation trades under the ticker ADPT on NASDAQ. Where is Adaptive Biotechnologies listed? Adaptive Biotechnologies Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:1HM; LS:A2PLR5. What is the SEC CIK of Adaptive Biotechnologies? The SEC Central Index Key (CIK) for Adaptive Biotechnologies Corporation is 1478320. Its filings are on SEC EDGAR. How many shares does Adaptive Biotechnologies have outstanding? 159,595,842 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Adaptive Biotechnologies listed under? Our directory records Adaptive Biotechnologies Corporation under United States. What does Adaptive Biotechnologies do? Our directory classifies Adaptive Biotechnologies Corporation as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Adaptive Biotechnologies? The ISIN recorded for Adaptive Biotechnologies Corporation is US00650F1093. Does aibio.space cover Adaptive Biotechnologies? aibio.space lists Adaptive Biotechnologies Corporation among 2,820 public biotech companies and publishes its news here as stories appear. Where is Adaptive Biotechnologies incorporated? SEC records list its state or country of incorporation as WA. What does Adaptive Biotechnologies develop? Adaptive Biotechnologies Corporation uses sequencing and computational biology to read the adaptive immune system and develop clinical products. Its MRD business uses a highly sensitive next-generation sequencing assay to measure minimal residual disease in hematologic malignancies. What is clonoSEQ clinical test from Adaptive Biotechnologies? clonoSEQ clinical test: NGS assay measuring MRD in lymphoid cancers Stage: FDA authorized for MM, B-ALL and CLL. What is clonoSEQ assay (MRD Pharma) from Adaptive Biotechnologies? clonoSEQ assay (MRD Pharma): MRD assay offered to biopharmaceutical partners for drug development ## Investor discussion: Adaptive Biotechnologies Members talk about Adaptive Biotechnologies (ADPT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Adaptive Biotechnologies, newest first. Each line links the filing it comes from. 1. 2026-06-15 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1478320/000119312526271117/d65233dex991.htm) 2. 2025-08-18 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1478320/000119312525182222/d59058d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ADPT on TradingView](https://www.tradingview.com/symbols/NASDAQ-ADPT/). ## SEC filings and registration - **SEC name**: Adaptive Biotechnologies Corp - **CIK**: 1478320 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ADPT (Nasdaq) - **State or country of incorporation**: WA - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 1165 EASTLAKE AVE E, SEATTLE, WA, 98109 - **Phone**: 206-659-0067 - **Shares outstanding**: 159,595,842 as of 2026-07-31 (10-Q filed 2026-08-04) - **Former names**: Adaptive TCR Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1478320/000119312526332940/adpt-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1478320/000119312526323753/adpt-20260724.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1478320/000119312526277516/d28937d8k.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1478320/000119312526271117/d65233d8k.htm) filed 2026-06-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1478320/000119312526263844/adpt-20260605.htm) filed 2026-06-09 - [10-Q](https://www.sec.gov/Archives/edgar/data/1478320/000119312526206546/adpt-20260331.htm) filed 2026-05-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/adpt-20260505.htm) filed 2026-05-05 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1478320/000119312526177409/adpt-20260423.htm) filed 2026-04-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001478320), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Adaptive Biotechnologies Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ADPT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Adaptive Biotechnologies Corporation - **Ticker**: ADPT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US00650F1093 - **Other listed symbols**: GETTEX:1HM; LS:A2PLR5 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ADPT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/adaptive-biotechnologies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Adaptive Biotechnologies (ADPT) news: offering", 2026-10-31, https://aibio.space/companies/adaptive-biotechnologies/